Antitumour necrosis factor alpha treatment in Crohn’s disease: long-term efficacy, side effects and need for surgery

References

• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Danese S, Colombel JF, Reinisch W, et al. Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther. 2011;33(8):857–869.
   PubMed Web of Science ®Google Scholar
• Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12(9):537–545.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369(8):754–762.
   PubMed Web of Science ®Google Scholar
• Hindryckx P, Vande Casteele N, Novak G, et al. The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug[s] for our patients? J Crohns Colitis. 2018;12(1):105–119.
   PubMed Web of Science ®Google Scholar
• Sprakes MB, Ford AC, Warren L, et al. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis. 2012;6(2):143–153.
   PubMed Web of Science ®Google Scholar
• O'Donnell S, Murphy S, Anwar MM, et al. Safety of infliximab in 10 years of clinical practice. Eur J Gastroenterol Hepatol. 2011;23(7):603–606.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009;58(4):492–500.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol. 2011;45(2):113–118.
   PubMed Web of Science ®Google Scholar
• Juillerat P, Sokol H, Froehlich F, et al. Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort. Inflamm Bowel Dis. 2015;21(1):60–70.
   PubMed Web of Science ®Google Scholar
• Eshuis EJ, Peters CP, van Bodegraven AA, et al. Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis. 2013;19(8):1622–1630.
   PubMed Web of Science ®Google Scholar
• Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2019;68(3):423–433.
   PubMed Web of Science ®Google Scholar
• Lo B, Vester-Andersen MK, Vind I, et al. Changes in disease behaviour and location in patients with Crohn's disease after seven years of follow-up: a Danish population-based inception cohort. J Crohns Colitis. 2018;12(3):265–272.
   PubMed Web of Science ®Google Scholar
• Jeuring SF, van den Heuvel TR, Liu LY, et al. Improvements in the long-term outcome of Crohn's disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort. Am J Gastroenterol. 2017;112(2):325–336.
   PubMed Web of Science ®Google Scholar
• Jeuring SFG, Biemans VBC, van den Heuvel TRA, et al. Corticosteroid sparing in inflammatory bowel disease is more often achieved in the immunomodulator and biological era-results from the dutch population-based IBDSL cohort. Am J Gastroenterol. 2018;113(3):384–395.
   PubMed Web of Science ®Google Scholar
• Buhl S, Steenholdt C, Rasmussen M, et al. Outcomes after primary infliximab treatment failure in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(7):1210–1217.
   PubMed Web of Science ®Google Scholar
• Casanova MJ, Chaparro M, García-Sánchez V, et al. Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study. Am J Gastroenterol. 2017;112(1):120–131.
   PubMed Web of Science ®Google Scholar
• Molander P, Farkkila M, Kemppainen H, et al. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. Scand J Gastroenterol. 2017;52(3):284–290.
   PubMed Web of Science ®Google Scholar
• Reenaers C, Mary JY, Nachury M, et al. Outcomes 7 years after infliximab withdrawal for patients with Crohn's disease in sustained remission. Clin Gastroenterol Hepatol. 2018;16(2):234–243.e2.
   PubMed Web of Science ®Google Scholar
• Torres J, Boyapati RK, Kennedy N, et al. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149(7):1716–1730.
   PubMed Web of Science ®Google Scholar
• Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6(11):1212–1217.
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19 Suppl A (Suppl A):5A–36A.
   PubMedGoogle Scholar
• de Wreede LC, Fiocco M, Putter H. Mstate: an r package for the analysis of competing risks and multi-state models. J Stat Softw. 2011;38(7):1–30.
   Web of Science ®Google Scholar
• Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014;63(1):88–95.
   PubMed Web of Science ®Google Scholar
• Wong ECL, Buffone E, Lee SJ, et al. End of induction patient-reported outcomes predict clinical remission but not endoscopic remission in Crohn's disease. J Crohns Colitis. 2021;15(7):1114–1119.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–2789.
   PubMed Web of Science ®Google Scholar
• Kamm MA, Hanauer SB, Panaccione R, et al. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011;34(3):306–317.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013;38(10):1236–1247.
   PubMed Web of Science ®Google Scholar
• Laharie D, D’Haens G, Nachury M, et al. Steroid-Free deep remission at one year does not prevent Crohn's disease progression: long-term data from the TAILORIX trial. Clin Gastroenterol Hepatol. 2021.DOI:https://doi.org/10.1016/j.cgh.2021.11.030.
   Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162–169.
   PubMed Web of Science ®Google Scholar
• Mooiweer E, Severs M, Schipper ME, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9(1):50–55.
   PubMed Web of Science ®Google Scholar
• Molander P, Kemppainen H, Ilus T, et al. Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. Scand J Gastroenterol. 2020;55(1):34–40.
   PubMed Web of Science ®Google Scholar
• Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci. 2008;53(4):1033–1041.
   PubMed Web of Science ®Google Scholar
• Rozich JJ, Holmer A, Singh S. Effect of lifestyle factors on outcomes in patients with inflammatory bowel diseases. Am J Gastroenterol. 2020;115(6):832–840.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice. J Crohns Colitis. 2020;14(5):694–709.
   PubMed Web of Science ®Google Scholar
• Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29(3):286–297.
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58(4):501–508.
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137(5):1628–1640.
   PubMed Web of Science ®Google Scholar
• Ponsioen CY, de Groof EJ, Eshuis EJ, et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol. 2017;2(11):785–792.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–1438.
   PubMed Web of Science ®Google Scholar
• Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25.
   PubMed Web of Science ®Google Scholar